Has the Swedish Pharma Industry valuation changed over the past few years?

Investors are relatively neutral on the Swedish Pharmaceuticals industry at the moment, indicating that they anticipate long term growth rates to remain steady. The industry is trading close to its 3-year average PS ratio of 9.3x.

Which industries have driven the changes within the Swedish Healthcare industry?

There are no additional sub-industries under this industry.

Swedish (OMX) Pharma Industry Analysis

Date	Market Cap	Revenue	Earnings	PE	Absolute PE	PS
Sun, 26 Jul 2026	SEK 46.0b	SEK 5.3b	-SEK 683,107,144.00	49x	-67.4x	8.7x
Tue, 23 Jun 2026	SEK 42.3b	SEK 5.3b	-SEK 1,275,205,144.00	63.2x	-33.1x	8x
Thu, 21 May 2026	SEK 44.0b	SEK 5.3b	-SEK 1,301,575,145.00	67.2x	-33.8x	8.3x
Sat, 18 Apr 2026	SEK 47.4b	SEK 5.4b	-SEK 1,189,677,671.00	64.4x	-39.9x	8.8x
Mon, 16 Mar 2026	SEK 40.7b	SEK 5.3b	-SEK 1,377,968,671.00	54.9x	-29.5x	7.7x
Wed, 11 Feb 2026	SEK 53.6b	SEK 5.3b	-SEK 1,467,275,157.00	57x	-36.5x	10.1x
Fri, 09 Jan 2026	SEK 51.1b	SEK 5.3b	-SEK 531,735,157.00	72.3x	-96.1x	9.6x
Sun, 07 Dec 2025	SEK 48.9b	SEK 5.3b	-SEK 531,735,157.00	69.3x	-91.9x	9.2x
Tue, 04 Nov 2025	SEK 51.3b	SEK 5.2b	-SEK 539,421,865.00	73.6x	-95.1x	9.9x
Thu, 02 Oct 2025	SEK 55.4b	SEK 5.1b	-SEK 405,183,865.00	70.6x	-136.6x	10.9x
Sat, 30 Aug 2025	SEK 57.9b	SEK 5.1b	-SEK 347,925,364.00	79.1x	-166.4x	11.4x
Mon, 28 Jul 2025	SEK 56.9b	SEK 5.0b	-SEK 375,088,364.00	78.3x	-151.7x	11.3x
Wed, 25 Jun 2025	SEK 49.9b	SEK 4.8b	-SEK 574,554,267.61	66.5x	-86.8x	10.3x
Fri, 23 May 2025	SEK 44.7b	SEK 4.8b	-SEK 597,209,985.84	60.8x	-74.8x	9.2x
Sun, 20 Apr 2025	SEK 47.4b	SEK 4.7b	-SEK 908,295,077.39	67.5x	-52.2x	10.1x
Tue, 18 Mar 2025	SEK 50.4b	SEK 4.7b	-SEK 809,591,734.45	72.6x	-62.2x	10.7x
Thu, 13 Feb 2025	SEK 51.0b	SEK 4.4b	-SEK 1,034,225,690.18	129.7x	-49.3x	11.5x
Sat, 11 Jan 2025	SEK 51.5b	SEK 4.4b	-SEK 615,804,485.39	132.8x	-83.7x	11.6x
Mon, 09 Dec 2024	SEK 50.2b	SEK 4.4b	-SEK 615,958,003.89	137.5x	-81.6x	11.3x
Wed, 06 Nov 2024	SEK 51.7b	SEK 4.3b	-SEK 682,172,453.00	135.1x	-75.8x	11.9x
Fri, 04 Oct 2024	SEK 64.8b	SEK 5.9b	-SEK 1,157,203,309.11	169.6x	-56x	11x
Sun, 01 Sep 2024	SEK 70.8b	SEK 5.9b	-SEK 1,166,314,026.00	187.7x	-60.7x	12x
Tue, 30 Jul 2024	SEK 68.3b	SEK 5.6b	-SEK 993,004,582.14	97.3x	-68.8x	12.2x
Thu, 27 Jun 2024	SEK 64.9b	SEK 6.4b	-SEK 862,402,299.62	76.2x	-75.3x	10.2x
Sat, 25 May 2024	SEK 53.3b	SEK 6.4b	-SEK 766,510,517.93	71.7x	-69.5x	8.4x
Mon, 22 Apr 2024	SEK 48.1b	SEK 6.2b	-SEK 1,040,638,863.10	76.1x	-46.2x	7.7x
Wed, 20 Mar 2024	SEK 50.7b	SEK 6.2b	-SEK 1,038,077,367.17	78.1x	-48.8x	8.1x
Fri, 16 Feb 2024	SEK 47.3b	SEK 6.0b	-SEK 910,781,956.72	56x	-51.9x	7.9x
Sun, 14 Jan 2024	SEK 73.1b	SEK 9.5b	-SEK 1,182,119,507.00	71.1x	-61.9x	7.7x
Tue, 12 Dec 2023	SEK 63.6b	SEK 9.5b	-SEK 1,184,556,936.00	58.1x	-53.7x	6.7x
Thu, 09 Nov 2023	SEK 54.0b	SEK 9.3b	-SEK 1,246,071,785.00	88.1x	-43.3x	5.8x
Sat, 07 Oct 2023	SEK 51.2b	SEK 9.2b	-SEK 1,180,563,470.00	116.3x	-43.4x	5.6x
Mon, 04 Sep 2023	SEK 51.3b	SEK 9.2b	-SEK 1,177,926,295.00	140.3x	-43.5x	5.6x
Wed, 02 Aug 2023	SEK 51.4b	SEK 8.9b	-SEK 1,414,080,981.00	88.5x	-36.3x	5.8x


SE Market	0.87%
Healthcare	-2.08%
Pharma	-3.16%
Pharma	-3.16%

Company	Last Price	7D	1Y	Valuation
FLERIE Flerie	SEK 20.80	4.3% +SEK 73.7m	-45.5%	PB0.5x
ALZCUR AlzeCure Pharma	SEK 6.28	4.0% +SEK 33.1m	116.6%	PB77.1x
IBT B Infant Bacterial Therapeutics	SEK 66.80	2.6% +SEK 22.9m	35.2%	PB10.9x
ONCOZ OncoZenge	SEK 6.86	12.5% +SEK 10.7m	4.9%	PS1357.3x
ERMA Enorama Pharma	SEK 0.33	26.9% +SEK 5.2m	-87.5%	PS11.3x

Announcement • Jul 21

Annexin Pharmaceuticals Updates on Nine Patients Treated in Nexus Study

Annexin Pharmaceuticals AB announced an update on the patient recruitment status in the NEXUS study. As of the announcement date, six patients with retinal vein occlusion (RVO) and three patients with diabetic retinopathy (DR) have been treated with the drug candidate ANXV. No limiting safety or tolerability findings have been reported. In RVO, three of the six patients have received a three days treatment, a reduction from five days in previously treated RVO patients. In DR a third patient was recently treated, which completes the intended first patient cohort. The company will analyse the data before deciding how to proceed with additional patient enrolment. Preliminary findings from seven evaluated patients who had been followed for between 15 and 120 days were described in a press release on June 23, 2026. The data reported corroborates the safety profile of ANXV and that signals of effect, both functional and anatomical, can be observed in the retina shortly after ANXV treatment. A signal of a beneficial systemic effect (reduction in neuropathic pain) has also been self-reported by a patient with non-proliferative diabetic retinopathy. In patients with RVO an improvement in retinal prefusion already after 1-2 doses of ANXV has prompted a reduction from five to three days of ANXV infusions in order to reduce the burden of treatment further. Whether durable effects on e.g. retinal perfusion are observed with the shorter ANXV treatment is under evaluation and will be a key element in the decision making process regarding additional patient recruitments. In patients with DR, the two patients so far evaluated, also show improvements in retinal perfusion and data from a third patient is emerging. Functional and anatomical changes together with analysis of levels of ANXV and other disease related factors in plasma will determine if the ANXV treatment should be modified, potentially as regards to duration or dose, before recruiting more patients with DR. The assessment if three days of ANXV treatment can potentially be effective, and thereby a preferred choice in Ph2b/3, is pending the data and the company is following the patients as regards retinal perfusion and requirement for standard of care treatments very closely. In DR, both local and systemic effect signals are observed. Data regarding ANXV, phosphatidyl serine (the molecular target), biomarkers of inflammation and microvascular parameters will be followed. The NEXUS study is a Phase 2a/proof of concept study with an adaptive design and includes patients with diabetic retinopathy (DR), where there is a clear impact on retinal blood vessels and blood supply, as well as newly diagnosed RVO patients. It is an open-label study without a placebo group or comparison with another treatment. The study is being conducted at The Retina Clinic London, UK, with Professor Paulo-Eduardo Stanga as Principal Investigator, and from May 2026 also at STZ eye trial, Department for Ophthalmology, University Hospital Tübingen, Germany, with Dr Immanuel P. Seitz as Principal Investigator. The study is planned to initially include three patients with DR, as well as three patients with newly diagnosed RVO. Patients are treated with ANXV for five days and followed up with detailed tests for 30 days, after which decisions are made regarding further patient recruitment. If the results are deemed promising, the intention within DR is to increase the number of patients and within RVO to study whether the treatment time can be shortened to three days, which was initiated in May 2026. All patients are followed less intensively for an additional 90 days to evaluate whether any effects persist. Both standard and high-advanced image analyses, functional and anatomical ophthalmological assessments, are performed monthly for four months following ANXV treatment. Evaluation is made of safety, tolerability and any signals of effect that may be related to ANXV. In addition to standardized tests of best corrected visual acuity (BCVA), the degree of diabetes-caused retinal damage, swelling of the retina and the need for anti-VEGF injections, objective functional tests and analyses of blood flow and vascular changes are performed. Initially, up to twelve patients in total are planned to be included in the study.

Swedish (OMX) Pharma Industry Analysis

Industry Valuation and Performance

Industry Trends

Top Stock Gainers and Losers

Latest News

New major risk - Financial position

Swedencare AB (publ) Earnings Missed Analyst Estimates: Here's What Analysts Are Forecasting Now

New major risk - Share price stability

New major risk - Share price stability

Chief Financial Officer recently bought kr110k worth of stock

Annexin Pharmaceuticals Updates on Nine Patients Treated in Nexus Study

Second quarter 2026 earnings: EPS and revenues miss analyst expectations

FDA Accepts Camurus NDA Resubmission for CAM2029 With December 2026 Review Date Set

AcuCort AB (publ) to Report Q2, 2026 Results on Aug 12, 2026

Newbury Pharmaceuticals Secures Generic Approval for Tofacitinib Newbury

Chief Executive Officer recently bought kr184k worth of stock

New minor risk - Shareholder dilution

Alzecure Pharma AB (Publ) Announces Board Changes

New minor risk - Share price stability

First quarter 2026 earnings released

We're Hopeful That Infant Bacterial Therapeutics (STO:IBT B) Will Use Its Cash Wisely